Parkinson's Disease Clinical Trial
Official title:
Kinematic and Neural Dynamics of Postural Instability in Parkinson's Disease
NCT number | NCT06405334 |
Other study ID # | E4810-R |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2024 |
Est. completion date | June 30, 2028 |
Balance problems and falls are among the most common complaints in Veterans with Parkinson's Disease (PD), but there are no effective treatments and the ability to measure balance and falls remains quite poor. This study uses wearable sensors to measure balance and uses deep brain stimulation electrodes to measure electric signals from the brain in Veterans with PD. The investigators hope to use this data to better understand the brain pathways underlying balance problems in PD so that new treatments to improve balance and reduce falls in Veterans with PD can be designed.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | June 30, 2028 |
Est. primary completion date | June 30, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Aims 1 and 2 Inclusion criteria: - All Veterans with a clinical diagnosis of Parkinson's disease as made by their treating neurologist in Hoehn and Yahr stage 2-3 with the ability to give informed consent will be considered for possible participation in this study. - Veterans cannot be past stage 3 as our measures depend on physical independence and fall risk prediction is less useful after stage 3. - Capacity to consent will be assessed with the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC). - A score of less than 14.5 will be used as the cut-off to decide whether a Veteran is capable of consenting as the false positive rate is zero below this score with marginal increases in sensitivity above this score (89% sensitivity, 100% specificity). Aim 3 Inclusion criteria: - In addition to the inclusion criteria for Aims 1 and 2, Veterans with an implanted STN DBS lead with a Percept device in place. Exclusion Criteria: Aims 1 and 2 Exclusion criteria: - Veterans with dementia of sufficient severity to impair their ability to make healthcare related decisions for themselves will be excluded. - Veterans with other forms of parkinsonism (PSP, CBGD, etc.) will be excluded. - Veterans past H&Y Stage 3 will be excluded. - Veterans with symptomatic orthostatic hypotension (defined as sustained drop in systolic blood pressure by 20 mmHg or diastolic blood pressure by 10 mmHg within 3 minutes of standing after being supine for five minutes) will also be excluded as this is an entity the investigators are not characterizing and could confound/bias the dataset. Aim 3: Exclusion criteria: - In addition to the exclusion criteria for Aims 1 and 2, Veterans with DBS leads implanted in other locations will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | Minneapolis VA Health Care System, Minneapolis, MN | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development | University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Event Identification Receiver Operating Characteristic Curve | All events are validated using the video camera recording. Using the CNN-LSTM algorithm, the investigators create a series of predicted events for the entire dataset of wearable sensor usage. For each event type, the investigators will then compare the predicted events based on this CNN-LSTM algorithm to the actual validated events. This will also allow us to assess the sensitivity, specificity, positive predictive value and negative predictive value for each event type.
Finally, the investigators will create separate receiver operating characteristic (ROC) curves and calculate the AUC for each event type. |
4 years | |
Primary | Silhouette Scores | All kinematic variables are first standardized using z-score conversion and then transformed into a new set of uncorrelated principal components that retain the original data's variation. Following dimensionality reduction with PCA, the investigators utilize k-means clustering to identify potential subgroups. K-means clustering partitions the data into distinct, non-overlapping subgroups based on minimizing within-cluster variance, with the optimal number of clusters determined through the elbow method. While k-means is the most common method and has been effective thus far, small sample size datasets typically fare better using hierarchical clustering. This method, conversely, constructs a hierarchy of clusters by iteratively combining the most similar clusters. Silhouette scores are calculated to assess how well separated the clusters are from each other. | 4 years | |
Primary | Associative STN alpha band power | Associative and motor STN will be parcellated and the DBS lead reconstructed based on our prior work. The investigators will then use bipolar LFP recordings from the appropriate contact pairs to construct time frequency histograms and examine the event-related modulation of power in the response preparation, movement execution and post-movement execution phases of the postural response. | 4 years | |
Primary | Postural step length response during associative STN vs. motor STN stimulation vs. no stimulation | The investigators will assess changes in reactive postural response kinematics to associative vs. motor vs. no STN stimulation to test whether any stimulation or stimulation location can improve PI. Linear mixed-effects models are used to test for within-patient changes in pull test kinematic parameters between groups. These models are adjusted for pull intensity, and baseline step length values. Models use a Bonferroni p-value correction to account for multiple testing. The investigators have previously been able to determine within-patient kinematic differences using our variable pull test method in a sample size of 13 movement disorder patients. With ~15 pull test trials for each condition, the investigators can demonstrate within-patient kinematic differences of about 5 cm in initial step length and 100 ms in reaction time. | 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |